Myelofibrosis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Future and investigational therapies involve immunomodulatory drugs, histone deacetylase inhibitors, newer generation drugs of already existing medications and drugs targeting pathways other than the JAK/STAT. | Future and investigational therapies involve immunomodulatory drugs, histone deacetylase inhibitors, newer generation drugs of already existing medications and drugs targeting pathways other than the JAK/STAT. The goal is to limit the need for allogeneic stem cell transplantation. | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
Revision as of 01:33, 11 December 2018
|
Myelofibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myelofibrosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Myelofibrosis future or investigational therapies |
|
Myelofibrosis future or investigational therapies in the news |
|
Risk calculators and risk factors for Myelofibrosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Future and investigational therapies involve immunomodulatory drugs, histone deacetylase inhibitors, newer generation drugs of already existing medications and drugs targeting pathways other than the JAK/STAT. The goal is to limit the need for allogeneic stem cell transplantation.
Future or Investigational Therapies
- Future or investigational therapies involve:
- Immunomodulatory drugs[1]
- Histone deactylase inhibitors
- Second-generation Janus kinase 1/2 inhibitors
References
- ↑ Zimran E, Keyzner A, Iancu-Rubin C, Hoffman R, Kremyanskaya M (November 2018). "Novel treatments to tackle myelofibrosis". Expert Rev Hematol. 11 (11): 889–902. doi:10.1080/17474086.2018.1536538. PMID 30324817.